This report was first published by Endpoints News. To see the original version, click here
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues.
The drugmaker published a new five-year business plan on Monday as it reported earnings for fiscal year 2025. Daiichi said it wants to become a top-five cancer company by 2035. It plans to achieve this goal by rapidly securing new approvals and expansions for antibody-drug conjugates developed using its DXd technology, which should help it pull in over 2.3 trillion Japanese yen ($14.6 billion) in 2030 oncology sales.
您已阅读21%（633字），剩余79%（2449字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。